Skip to content
OpenCapital
Get started

Denali Therapeutics Inc. DNLI Cash & Equivalents

Cash & Equivalents at other companies

Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.97B-4.0%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$118.12M+211%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$282.21M+29.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$882.02M+62.5%
Biogen logo
BiogenBIIB
$3.38B+30.2%

Other financials

Income statement

See full
Revenue-—
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.7B+54.2%
Enterprise value$3.35B+37.1%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0×0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s cash & equivalents?
Denali Therapeutics Inc. (DNLI) reported cash & equivalents of $390.73M in Q1 2026.
How has Denali Therapeutics Inc.'s cash & equivalents changed year-over-year?
Denali Therapeutics Inc.'s cash & equivalents increased by 550.6% year-over-year, from $60.05M to $390.73M.
What is the long-term trend for Denali Therapeutics Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s cash & equivalents has grown at a -16.3% compound annual growth rate (CAGR), from $508.64M to $208.43M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.